 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Order of treatment of choice for BRAFV600 mutant metastatic melanoma

J Clin Oncol: Order of treatment of choice for BRAFV600 mutant metastatic melanoma

 Last Update: 2022-10-12
 Source: Internet
 Author: User

Tags

adenocarcinoma survival rate

free journal template

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

PD-1/CTLA-4 combined blockade and BRAF/MEK double inhibition have shown significant clinical benefit

In a Phase 3 clinical trial, untreated BRAFV600 mutant metastatic melanoma was randomly divided into two groups, the first step receiving nalvozumab + ipizumab (group A) or dalafinil + trametinib (group B), and after the progression of the disease, proceeding to the second step, switching to a treatment regimen, dalafinil + trametinib (group C) or nalvozumab + ipizumab (group D).

A total of 265 patients were recruited and 73 were enrolled in the second step of treatment (27 in group C and 46 in group D

In summary, if necessary, nivolumab plus ipizumab followed by BRAF and MEK inhibitors may be the order

Original Source:

Michael B.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.